3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Breast Neoplasms
104
Neoplasms
13
Neoplasm Metastasis
8
Sarcoma
6
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Melanoma
5
Leukemia, Myeloid, Acute
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Prostatic Neoplasms
4
Lung Neoplasms
4
Liposarcoma
4
Multiple Myeloma
3
Head and Neck Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Colonic Neoplasms
3
Breast Diseases
3
Brain Neoplasms
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm, Residual
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Inflammation
2
Estrogen Receptor-positive Breast Cancer
2
Esophageal Squamous Cell Carcinoma
2
Interventions
Imatinib Mesylate
32
regorafenib
9
Sunitinib
9
Laparoscopy
5
Dasatinib
4
Blood Specimen Collection
4
pazopanib
3
nilotinib
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Observation
3
spartalizumab
2
ripretinib
2
envafolimab
2
binimetinib
2
apatinib
2
Temozolomide
2
Neoadjuvant Therapy
2
Ipilimumab
2
Gemcitabine
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
Capecitabine
2
CTLA-4 Antigen
2
Biopsy, Fine-Needle
2
Biopsy
2
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastrointestinal Stromal Tumors
×
palbociclib
×
Clear all
NCT01907607
2025-08-24
CYCLIGIST
Institut Bergonié
Phase 2
Completed
29 enrolled
8 charts